Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by 99942Apophison Nov 17, 2021 3:09pm
702 Views
Post# 34137617

Dr. Vera Madzarevic

Dr. Vera Madzarevic I am so impressed with Dr. Vera Madzarevic being hired and with her high degree of experience that I actually feel even more confident that the path forward for Theralase has just taken a big stride forward. This truly IMO also shows the level of their confidence for hiring such extreme talent, they hired her for success. Well done Theralase. 

Effective October 25, 2021, Dr. Vera Madzarevic, Ph.D. will assume the role of Director of Clinical Development and Quality Assurance reporting to Dr. Mandel.

Dr. Madzarevic holds a Ph.D. in both clinical pharmacology and biochemistry and brings over 25 years of global experience in clinical research and quality assurance in the biopharmaceutical and medical device industry to Theralase®.

For the last 20 years, Dr. Madzarevic has been the Global Director, Clinical Research Services and Medical Affairs for Global Research Pharma Canada, a contract Clinical Research Organization (“CRO”), where she was involved in all phases of clinical development (Phase I to IV), training, product development, strategic planning and for implementing, monitoring and managing clinical and scientific activities for clients worldwide.

Prior to this appointment, she was employed as a senior clinical research scientist for Novartis Pharmaceuticals based in New Jersey, USA.

Dr. Madzarevic, appointed Director of Clinical Development and Quality Assurance at Theralase® stated, “It is a pleasure to join the Theralase® clinical research team, reporting to Dr. Mandel. I feel my extensive global experience in clinical research and quality assurance will support the Company’s primary objective of successfully developing with the objective of commercializing its Anti-Cancer Therapy (“ACT”) technology.”

<< Previous
Bullboard Posts
Next >>